| abstract |
The invention relates to the use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate the carbohydrate part of said gangliosides in terms of binding to anti-AGm1 antibodies and/or anti-Gm1 antibodies, for producing an agent which blocks or binds to anti-AGm1 antibodies and/or anti-Gm1 antibodies which bind to natural killer cells (NKC), said agent being administered to patients at high risk of sepsis and to patients with sepsis, in whom such antibodies have been detected, for the prevention, inhibition and treatment of sepsis. |